Neurizon Therapeutics Limited (ASX:NUZ)
Australia · Delayed Price · Currency is AUD | Market Cap | 53.11M -6.2% |
| Revenue (ttm) | 5.98M +294.5% |
| Net Income | -14.85M |
| EPS | -0.03 |
| Shares Out | 708.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 338,365 |
| Average Volume | 629,348 |
| Open | 0.0790 |
| Previous Close | 0.0790 |
| Day's Range | 0.0750 - 0.0790 |
| 52-Week Range | 0.0750 - 0.1850 |
| Beta | 1.27 |
| RSI | 39.29 |
| Earnings Date | Apr 21, 2026 |
About Neurizon Therapeutics
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neur... [Read more]
Financial Performance
In fiscal year 2025, Neurizon Therapeutics's revenue was 1.54 million, an increase of 82.70% compared to the previous year's 841,713. Losses were -16.59 million, 116.3% more than in 2024.
Financial StatementsNews
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS Approximately 160 participants with ALS will be ...
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
Highlights: FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Plat...